Study guide

13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

Philippine Physician Licensure Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: PLE Structure, Eligibility & Study Strategy

1.1 PLE Format, 2026 Schedule & the Statutory Passing Rule 1.2 Eligibility, Internship, PRC Filing & Test-Day Rules 1.3 Reading the 2025 Tables of Specifications & Building a Study Plan

2 Chapter 2: Physiology I: Cells, Blood, Nerve & Muscle

2.1 Homeostasis, Cell Function, Membrane Transport & Resting Potential 2.2 Blood Cells, Immunity, Hemostasis, Fibrinolysis & Blood Distribution 2.3 Action Potentials, Conduction, the Neuromuscular Junction & Muscle Contraction

3 Chapter 3: Physiology II: Cardiovascular & Respiratory Systems

3.1 Cardiac Electrophysiology, the Cardiac Cycle & the Heart as a Pump 3.2 Circulation: Resistance, Venous Return, Coronary Flow, Microcirculation & Fetal Circulation 3.3 Respiratory Mechanics, Gas Exchange, Gas Transport, Control of Breathing & Extreme Environments

4 Chapter 4: Physiology III: Gastrointestinal, Endocrine, Renal & Reproductive Systems

4.1 Gastrointestinal Physiology: Secretion, Motility, Digestion & Absorption 4.2 Endocrine Physiology: Hormone Chemistry, Axes, Calcium & Fuel Regulation 4.3 Renal Physiology, Body Fluid Balance & Acid-Base Regulation 4.4 Reproductive Physiology: Sexual Differentiation, Spermatogenesis, the Menstrual Cycle, Parturition & Lactation

5 Chapter 5: Physiology IV: Neurophysiology & Special Senses

5.1 Sensory Receptors, Somatic Sensation, Spinal Reflexes & Motor Control 5.2 Higher Brain Functions, Sleep, the Autonomic Nervous System, Cerebral Blood Flow & the Special Senses

6 Chapter 6: Legal Medicine I: Medicolegal Examination, Identification & Death

6.1 The Medicolegal Examination, Physical Evidence & the Crime Scene 6.2 Identification of the Living, the Dead & Skeletal Remains 6.3 Thanatology: Death, Brain Death, Postmortem Changes & Time of Death

7 Chapter 7: Legal Medicine II: Injuries, Sexual Crimes, Reproduction, Mental State & Poisoning

7.1 Physical Injuries: Revised Penal Code Classes, Wounds, Gunshot Injuries, Asphyxia & Burns 7.2 Sexual Crimes, Violence Against Women & Child Abuse 7.3 Medicolegal Aspects of Pregnancy, Delivery, Abortion, Infanticide, Paternity & Marriage 7.4 Disturbance of Mentality: Insanity, Intoxication, Capacity & the Mental Health Act 7.5 Forensic Toxicology & Poisoning: Diagnosis, Evidence, Antidotes & Philippine Laws

8 Chapter 8: Legal Medicine III: Reports, Regulation, Liability & Ethics

8.1 The Medicolegal Report, the Death Certificate, Autopsy Rules & Communicating with Relatives 8.2 Licensure & Regulation of Medical Practice: RA 2382, the Board of Medicine, PRC & Prescribing Laws 8.3 Medical Malpractice: Civil, Criminal & Administrative Liability and Key Philippine Doctrines 8.4 Physician Relationships Under the PMA Code of Ethics: Patients, Colleagues, Allied Health, Students, Industry, HMOs, Hospitals & PhilHealth 8.5 Bioethical Principles, Informed Consent, Confidentiality, End-of-Life & Research Ethics

9 Chapter 9: Pathology I: Cell Injury, Inflammation & Hemodynamics

9.1 Cell Injury, Adaptation, Necrosis, Apoptosis, Accumulations & Calcification 9.2 Acute & Chronic Inflammation, Granulomas, Systemic Effects & Tissue Repair 9.3 Hemodynamic Disorders: Edema, Hemorrhage, Thrombosis, Embolism, Infarction, DIC & Shock

10 Chapter 10: Pathology II: Genetics, Neoplasia, Immunity, Environment & Infection

10.1 Genetic Disorders & Neoplasia: Mendelian, Chromosomal, Non-Classic Inheritance, Tumor Biology & Markers 10.2 Immunopathology: Hypersensitivity, Autoimmunity, Immunodeficiency & Transplant Rejection 10.3 Environmental & Nutritional Pathology: Air Pollution, Tobacco, Metals, Occupational Lung Disease & Deficiency States 10.4 Pathology of Infectious Diseases: Transmission, Tissue Reaction Patterns & Diagnostic Morphology

11 Chapter 11: Pathology III: Gastrointestinal, Cardiovascular & Respiratory Pathology

11.1 Gastrointestinal, Hepatic, Biliary & Pancreatic Pathology 11.2 Cardiovascular & Collagen Pathology: Heart Failure, Congenital, Ischemic, Hypertensive, Valvular, Pericardial & Myocardial Disease 11.3 Respiratory Pathology: Atelectasis, Edema, ARDS, Obstructive & Restrictive Disease, Vascular Disease, Infections, Tumors & Pleura

12 Chapter 12: Pathology IV: Hematopoietic, Genitourinary, Endocrine & Nervous System Pathology

12.1 Hematopoietic Pathology: Anemias, Polycythemia, Bleeding Disorders, DIC & Lymphoid and Myeloid Neoplasms 12.2 Genitourinary Pathology: Glomerular, Tubulointerstitial, Vascular & Cystic Kidney Disease, Renal Tumors, Obstruction & Genital Disorders 12.3 Endocrine Pathology: Pancreas, Adrenal, Parathyroid, Thyroid & Pituitary Disorders 12.4 Nervous System Pathology: Cerebrovascular Disease, Edema & Herniation, Infections, Degenerative & Demyelinating Disease, Tumors

13 Chapter 13: Biochemistry I: Carbohydrate, Protein, Genetic & Energy Biochemistry

13.1 Carbohydrate Chemistry, Digestion, Glycolysis, Pyruvate Dehydrogenase & the Pentose Phosphate Pathway 13.2 Gluconeogenesis, Glycogen, Lipogenesis, Ketogenesis & Hormonal Control of Fuel Metabolism 13.3 Protein Digestion, Amino Acid Catabolism, the Urea Cycle, Heme Synthesis, Porphyrias & Bilirubin Metabolism 13.4 Amino Acids & Proteins: Structure, Properties, Separation, Specialized Products, Collagen & Protein Misfolding in Alzheimer Disease 13.5 Molecular Genetics & Enzymes: Replication, Repair, Gene Expression, Molecular Techniques, Lysosomal Storage Diseases & Enzyme Kinetics 13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

14 Chapter 14: Biochemistry II: Respiratory, Nutritional, Immunologic & Cardiovascular Biochemistry

14.1 Respiratory Biochemistry: Hemoglobin, Oxygen Binding, Hemoglobinopathies, Thalassemias, Methemoglobin, Buffers & Acid-Base Balance 14.2 Nutrition Biochemistry: Dietary Standards (RENI to PDRI 2015), Food Guides, Protein Quality, Energy Expenditure, Breast Milk, Vitamins, Minerals & Blood Components 14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC 14.4 Cardiovascular Biochemistry: Cholesterol, Lipoproteins, Dyslipidemias, Atherogenesis, Myocardial Energetics, Biomarkers & Heart Failure

15 Chapter 15: Anatomy I: Thorax, Abdomen, Pelvis & Back

15.1 Thorax: Thoracic Wall, Breast, Pleura & Lungs, Mediastinum, Heart & Great Vessels 15.2 Abdomen: Abdominal Wall & Inguinal Region, Peritoneum, Viscera, Diaphragm & Posterior Abdominal Wall 15.3 Pelvis & Perineum: Bony Pelvis, Pelvic Floor, Pelvic Viscera, Vessels & Nerves, Perineal Pouches & the Anal Canal 15.4 Back & Spinal Column: Vertebrae, Curvatures, Joints, Back Muscles, Spinal Cord, Meninges & Cord Syndromes

16 Chapter 16: Anatomy II: Upper Limb, Lower Limb & Skin

16.1 Upper Limb: Bones, Superficial Veins, Shoulder Muscles, Axilla & Brachial Plexus, Arm, Cubital Fossa, Forearm, Hand & Joints 16.2 Lower Limb: Bones, Venous & Lymphatic Drainage, Thigh, Gluteal Region, Popliteal Fossa, Leg Compartments, Foot, Joints & Gait 16.3 Skin & Appendages: Epidermis, Junctions, Dermis, Subcutaneous Tissue, Fascia, Nerves, Vessels, Lymphatics, Hair, Nails & Glands

17 Chapter 17: Anatomy III: Head, Neck & Histology

17.1 Head I: Skull & Cranial Foramina, Scalp, Face & Parotid, Orbit, Temporal & Infratemporal Fossae, TMJ, Oral Region, Nose & Ear 17.2 Head II: Meninges & Dural Venous Sinuses, Brain Regions & Ventricles, Blood Supply, Cranial Nerves, Pituitary & Pineal, Brainstem Syndromes 17.3 Neck: Cervical Vertebrae & Hyoid, Fascial Layers, Superficial Muscles, Triangles, Root of the Neck, Visceral Layers & Lymphatics 17.4 Histology: Cells, Epithelium & Glands, Connective Tissue & Fat, Cartilage & Bone, Blood & Hematopoiesis, Muscle, Nerve, Vessels, Lymphoid Organs & Organ Histology

18 Chapter 18: Microbiology I: Foundations, Respiratory & Cardiovascular Infections

18.1 Microbiology Foundations: The Organ-System TOS, Specimens & Stains, Gram-Positive and Gram-Negative Bacteria 18.2 Respiratory Infections: Tonsillitis, Sinusitis & Mastoiditis, Bronchitis, Community-Acquired & Severe Pneumonia, Bronchiectasis and Paragonimiasis 18.3 Tuberculosis, Leprosy & Nontuberculous Mycobacteria: Pathogenesis, Diagnosis, NTP Regimens & Prevention 18.4 Cardiovascular Infections: Infective Endocarditis, Rheumatic Fever & Rheumatic Heart Disease, Myocarditis, Pericarditis and Septic Thrombophlebitis

19 Chapter 19: Microbiology II: Gastrointestinal & Nervous System Infections

19.1 Gastrointestinal Infections I: Gastroenteritis & Enterocolitis, Cholera, Typhoid & Salmonellosis, Shigellosis, Food Poisoning and Viral Hepatitis 19.2 Gastrointestinal Infections II: Amebiasis, Giardiasis & Cryptosporidiosis, Soil-Transmitted Helminths, Pinworm, Capillariasis and Tapeworms 19.3 Nervous System Infections: Meningitis & CSF Patterns, Encephalitis, Rabies and DOH PEP, Spinal Cord Infections, Tetanus & Botulism, Paralytic Shellfish Poisoning

20 Chapter 20: Microbiology III: Genitourinary, Reproductive, Blood & Skin Infections

20.1 Genitourinary Infections: Cystitis & Pyelonephritis, Urine Diagnostics, Urethritis, Balanoposthitis, Pelvic Inflammatory Disease and Genital Ulcers 20.2 Reproductive Tract Infections & STIs: Syphilis, Genital & Neonatal Herpes, HPV, Molluscum, CMV, Trichomoniasis & Vaginitis, Cervicitis, Prostatitis and Orchitis 20.3 Hematopoietic & Lymphatic Infections: Dengue and Other Hemorrhagic Fevers, Malaria, Lymphatic Filariasis, Lymphogranuloma Venereum and Epstein-Barr Virus 20.4 Integumentary Infections: Viral Exanthems (Measles, Mumps, Rubella, Varicella, Smallpox & Mpox, Fifth Disease), Herpesviruses, Fungal Skin Infections and Tick-Borne Diseases

21 Chapter 21: Microbiology IV: Musculoskeletal & Multisystemic Infections

21.1 Musculoskeletal & Soft-Tissue Infections: Osteomyelitis, Septic & Reactive Arthritis, Pyomyositis & Gas Gangrene, Cellulitis, Necrotizing Fasciitis and Bite Wounds 21.2 Multisystemic Infections I: Septicemia, Septicopyemia & Septic Shock, Leptospirosis and Schistosomiasis japonica 21.3 Multisystemic Infections II: HIV/AIDS Virology, the Philippine Epidemic & RA 11166, Diagnosis (rHIVda), ART, Prevention and Opportunistic Infections including Toxoplasmosis

22 Chapter 22: Obstetrics I: Prenatal Care, Labor & Obstetric Bleeding

22.1 Prenatal Care: Diagnosis of Pregnancy, Maternal Physiology, Dating, Nutrition & Supplements, Screening Tests and the DOH Antenatal Package 22.2 Labor & Parturition: Signs of Labor, Pelvis and Passenger, Stages and Cardinal Movements, Partograph, Fetal Monitoring, Dystocia, Shoulder Dystocia, Operative Delivery, Preterm Labor, PROM and Adolescent Pregnancy 22.3 Early Pregnancy Risks & Bleeding: Hyperemesis, Spontaneous Abortion, Recurrent Loss & Cervical Insufficiency, Ectopic Pregnancy, Hydatidiform Mole & Gestational Trophoblastic Neoplasia 22.4 Hemorrhagic Complications of Pregnancy: Placenta Previa, Abruption, Vasa Previa, Placenta Accreta Spectrum, Uterine Rupture, Third-Stage Management and Postpartum Hemorrhage

23 Chapter 23: Obstetrics II: Fetal, Hypertensive, Medical, Infectious & Postpartum Problems

23.1 Fetal Complications: Malpresentation & Breech, Macrosomia, Fetal Growth Restriction, Amniotic Fluid Disorders, Antepartum Surveillance, Rh Alloimmunization, Multiple Gestation and Post-Term Pregnancy 23.2 Hypertension & Diabetes in Pregnancy: Classification, Preeclampsia Pathogenesis and Prevention, Severe Features, Eclampsia & HELLP, Magnesium Sulfate, Gestational and Pregestational Diabetes 23.3 Medical & Surgical Disorders in Pregnancy: Drug Pharmacokinetics, Epilepsy, Thyroid, Heart Disease, SLE & APS, Asthma, Liver Disorders, Anemia, Dermatoses, Appendicitis, Gallstones, Stones and Trauma 23.4 Perinatal Infections: Triple Elimination (HIV, Syphilis, Hepatitis B), Group B Streptococcus, Chorioamnionitis, Gonorrhea & Chlamydia, Condyloma, Herpes and the TORCH Infections 23.5 Postpartum Care & Complications: Normal Puerperium, Postnatal Visits, Breastfeeding, Puerperal Fever and Infection, Mastitis, Late Hemorrhage, Mood Disorders, VTE and Postpartum Contraception

24 Chapter 24: Gynecology I: Benign Disorders, Infections & Contraception

24.1 Benign Lower Genital Tract Disorders & Pelvic Floor: Vulvar Dermatoses, Bartholin Cysts, Vaginal and Cervical Lesions, Premalignant Lesions, Pelvic Organ Prolapse, Urinary Incontinence and Fistula 24.2 Benign Upper Genital Tract Disorders: Leiomyoma, Adenomyosis & Endometriosis, Endometrial Polyps and Hyperplasia, Functional Cysts and Benign Ovarian Tumors, Adnexal Torsion and Tubal Disease 24.3 Infections of the Female Reproductive Tract: Burden & Screening, Syndromic Management, Vaginitis and Cervicitis, Pelvic Inflammatory Disease & Tubo-Ovarian Abscess, Genital Tuberculosis and Toxic Shock 24.4 Contraception & Family Planning: The RH Law, Effectiveness, Natural and Barrier Methods, Hormonal Methods, IUDs, Permanent Methods, Emergency Contraception and the WHO Eligibility Criteria

25 Chapter 25: Gynecology II: Reproductive Endocrinology, Oncology & Special Issues

25.1 Reproductive Endocrinology & Menstrual Disorders: The Menstrual Cycle, Puberty, Abnormal Uterine Bleeding (PALM-COEIN), Amenorrhea, PCOS, Hyperprolactinemia, Dysmenorrhea, Infertility, Menopause, HRT and Osteoporosis 25.2 Gynecologic Oncology: Cervical Cancer Screening, Staging & Treatment, Endometrial Cancer and Lynch Syndrome, Ovarian Tumors and BRCA, Vulvar and Vaginal Cancer, Survival and Quality of Life 25.3 Contemporary Issues & Pediatric and Adolescent Gynecology: Violence Against Women, Sexual Assault Care, Breast Disorders, Ethics of Maternal-Fetal Conflict, and Gynecologic Problems of Children and Adolescents

26 Chapter 26: Pediatrics I: Newborn, Growth, Nutrition, Immunization & Infections

26.1 The Newborn: Normal Findings and Variants, EINC (Unang Yakap), APGAR, Neonatal Resuscitation, Routine Care & Newborn Screening, Jaundice, Respiratory Distress, Hypoglycemia and Neonatal Sepsis 26.2 Growth, Development & Nutrition: Growth Parameters, Milestones and Red Flags, Speech Delay, Autism, ADHD & Global Delay, Breastfeeding and Feeding, Micronutrient Deficiencies, Malnutrition and Obesity 26.3 Immunization: RA 10152 and the National Immunization Program Schedule, Fully Immunized Child, School-Based Immunization, Other Recommended Vaccines, Vaccine Types, Cold Chain, Contraindications and AEFI 26.4 Pediatric Infectious Diseases: Bacterial (Diphtheria to Congenital Syphilis), Childhood TB, Viral Exanthems and Infections, Dengue in Children, Pediatric HIV, Protozoal, Helminthic and Fungal Infections

27 Chapter 27: Pediatrics II: Respiratory, Cardiovascular, Neurologic & Gastrointestinal Disorders

27.1 Pediatric Respiratory Disorders: IMCI Danger Signs and Cough Assessment, URI, Tonsillitis & Peritonsillar Abscess, Croup, Epiglottitis, Foreign Body, Bronchiolitis, Pneumonia, Pleural Effusion and Complications 27.2 Pediatric Cardiovascular & Collagen Disorders: Heart Sounds and Murmurs, Acyanotic and Cyanotic Congenital Heart Disease, Eisenmenger, Hypercyanotic Spells, Heart Failure, Rheumatic Fever, Hypertension, Endocarditis, Kawasaki, SLE, JIA, Dermatomyositis and Pediatric Resuscitation 27.3 Pediatric CNS Disorders: Febrile Seizures, Epilepsy Syndromes, Status Epilepticus, Meningitis and Encephalitis in Children, Cerebral Palsy, Hydrocephalus & Neural Tube Defects, Headache and Migraine, and Brain Tumors 27.4 Pediatric GI Disorders & Poisoning: Vomiting (Pyloric Stenosis, Atresias, Malrotation, Intussusception, GERD), Diarrhea and IMCI Rehydration Plans, Abdominal Pain, Constipation & Hirschsprung, Jaundice, Biliary Atresia & Choledochal Cyst, Hepatitis, Food Allergy, and Kerosene, Aspirin and INH Poisoning

28 Chapter 28: Pediatrics III: Genitourinary, Endocrine, Hematologic & Oncologic Disorders

28.1 Pediatric Genitourinary Disorders & Child Abuse: UTI and Vesicoureteral Reflux, Post-Streptococcal GN and Other Nephritides, Nephrotic Syndrome, AKI and HUS, CKD, Congenital Urogenital Anomalies, and Recognizing and Reporting Child Abuse 28.2 Pediatric Endocrine & Metabolic Disorders: Short Stature and Growth Hormone, Gigantism, Diabetes Insipidus, Congenital Hypothyroidism, Graves Disease & Goiter, Type 1 Diabetes and DKA, Congenital Adrenal Hyperplasia, Cushing Syndrome, Pheochromocytoma and Adrenal Crisis 28.3 Pediatric Hematology, Allergy & Immunology: Normal Hemogram and Immunoglobulins by Age, Anemias (Iron Deficiency, Thalassemia, G6PD, Spherocytosis, Aplastic), Bleeding Disorders (ITP, Hemophilia, vWD, DIC, Vitamin K), IgA Vasculitis, Rashes and Drug Reactions, Asthma, Allergic Rhinitis and Primary Immunodeficiencies 28.4 Pediatric Oncology & Genetics: Leukemias and Lymphomas, Retinoblastoma, Wilms Tumor, Neuroblastoma, Ewing Sarcoma and Osteosarcoma; Sex Chromosome and Autosomal Disorders, Inborn Errors of Metabolism and the Dysmorphic ("Odd-Looking") Child

29 Chapter 29: Preventive Medicine I: The Physician as Health Care Provider

29.1 The Physician as Health Care Provider I: Natural History of Disease, Disease Causation, Levels of Prevention and Primary Care Across the Clinical Rotations 29.2 The Physician as Health Care Provider II: The Filipino Family and Family Assessment Tools, Health Education and Promotion, Behavior Change Models and Geriatric Medicine 29.3 The Physician as Health Care Provider III: The Primary Health Care Concept (Alma-Ata, Astana, Philippine PHC) and Mental Health in Primary Care under RA 11036

30 Chapter 30: Preventive Medicine II: Philippine Health Care System & Community Medicine

30.1 The Philippine Health Care System: DOH Structure, Levels of Care and Referral, Devolution under RA 7160, the Universal Health Care Act (RA 11223), PhilHealth and YAKAP, and Leading Causes of Morbidity and Mortality 30.2 Epidemiology, Surveillance & Outbreaks: Measures of Disease Occurrence and Association, Rates, Endemic and Epidemic Levels, PIDSR and RA 11332 Notifiable Diseases, the Ten Steps of Outbreak Investigation and Epidemic Curves 30.3 DOH Programs & Environmental Sanitation: TB, Dengue, Rabies, Leprosy, Helminth and Other Disease Programs; the Sanitation Code (PD 856), Water Supply and Potability, Excreta and Solid Waste, Food Sanitation and Health Care Waste 30.4 Community Medicine: Principles of Public Health Administration and Program Planning, Vital Health Indices (Infant and Maternal Mortality), the Ecologic Concept of Health, Lifestyle and Non-Communicable Diseases, Health-Seeking Behavior and Traditional Medicine

31 Chapter 31: Preventive Medicine III: Manager, Researcher & Social Mobilizer

31.1 The Physician as Administrative Manager: Communication and Interpersonal Skills, Teamwork, Adult Learning, Occupational Health (RA 11058), Bioethics, Palliative Care, School Health, Organ Transplantation and Birth and Death Certificates 31.2 The Physician as Researcher I: The Research Process and Proposal, Research Ethics, Study Designs and Meta-Analysis, Demography and Vital Statistics, Evidence-Based Medicine and Quality Assurance 31.3 The Physician as Researcher II: Biostatistics (Data Types, Distributions, Central Tendency and Dispersion, Confidence Intervals, Hypothesis Testing and Test Selection) and Screening Tests (Validity, Predictive Values, Likelihood Ratios, Biases and Program Criteria) 31.4 The Physician as Social Mobilizer and Leader: Philippine Health Laws, Decrees and Executive Orders, Principles of Social Mobilization and Community Organizing, and Disaster Risk Reduction and Management in Health

32 Chapter 32: Pharmacology I: Principles, Cardiovascular & Nervous System Therapeutics

32.1 Pharmacology Foundations: The Pharmacology TOS, Pharmacokinetics, Drug Metabolism and Interactions, Pharmacodynamics, Adverse Drug Reactions and Monitoring, Autonomic Pharmacology, and Philippine Prescribing Rules 32.2 Cardiovascular Pharmacology I: Cardiac Arrest and ACLS Drugs, Bradycardia and Complete Heart Block, Antiarrhythmics, Anticoagulation in Atrial Fibrillation, Antianginals, ACS Therapy and Fibrinolysis, Pericarditis and Endocarditis Regimens 32.3 Cardiovascular Pharmacology II: Antihypertensives and Diuretics, Hypertensive Emergencies, Vasopressors and Inotropes in Shock, Heart Failure GDMT and Digoxin, and Lipid-Lowering Therapy 32.4 Nervous System Pharmacology I: Antiseizure Drugs and Status Epilepticus, Headache and Migraine, Vertigo, Stroke Thrombolysis and Secondary Prevention, Encephalopathy, Dementia, ADHD, Parkinson Disease and Movement Disorders, Raised Intracranial Pressure and CNS Infections

33 Chapter 33: Pharmacology II: Psychiatric, Respiratory & Genitourinary Therapeutics

33.1 Nervous System Pharmacology II: Antidepressants and Their Toxicity, Serotonin Syndrome, Anxiolytics and Hypnotics, Antipsychotics, EPS and NMS, Lithium and Mood Stabilizers, Sleep Disorders, Agitation and Alcohol Withdrawal 33.2 Respiratory Pharmacology: Cough and Colds, Allergic Rhinitis, Asthma (Controllers, Relievers, Exacerbations), COPD, Anti-TB Drugs, Antibiotics for Pneumonia and Bronchitis, and Lung Cancer Therapy 33.3 Genitourinary Pharmacology I: Antimicrobial Classes and Toxicities, and Drug Treatment of UTI, Pyelonephritis, Gonorrhea, Chlamydia, Syphilis, Genital Herpes, Genital Warts, PID, Vaginitis, Prostatitis and Orchitis 33.4 Genitourinary Pharmacology II: Kidney Stones, Nephrotic and Nephritic Disease, Drug Dosing in Kidney Disease and Hyperkalemia, Benign Prostatic Hyperplasia, Erectile Dysfunction, Renal Cell Carcinoma and Prostate Cancer Therapy

34 Chapter 34: Pharmacology III: Digestive, Endocrine, Skin & Musculoskeletal Therapeutics

34.1 Digestive Pharmacology: Portal Hypertension and Variceal Bleeding, Acid-Peptic Disease, H. pylori and GERD, Antiemetics, Laxatives and Antidiarrheals, Biliary and Pancreatic Disease, GI Infections and Parasites, Viral Hepatitis, C. difficile, Candidiasis and GI Cancer Chemotherapy 34.2 Endocrine Pharmacology I: Diabetes Mellitus Drugs (Metformin, Sulfonylureas, SGLT2 Inhibitors, GLP-1 Agonists, DPP-4 Inhibitors, Thiazolidinediones, Insulins), Choosing Therapy by Comorbidity, DKA and HHS, and Hypoglycemia 34.3 Endocrine Pharmacology II: Pituitary Disorders (GH Deficiency, Acromegaly, Prolactinoma, Diabetes Insipidus, Panhypopituitarism), Thyroid Drugs and Thyroid Storm, Calcium and Parathyroid Disorders, Adrenal Disorders and Corticosteroids 34.4 Cutaneous and Musculoskeletal Pharmacology: Cellulitis and Abscess, Drug-Induced Skin Reactions (SJS/TEN), Pain Management (Paracetamol, NSAIDs, Opioids), Osteoporosis, Rheumatoid Arthritis and Osteoarthritis, Septic and TB Arthritis, Gout, SLE and Psoriasis

35 Chapter 35: Surgery I: Basic Surgical Principles

35.1 Basic Surgical Principles I: The Surgery TOS, Fluids and Electrolytes, Acid-Base Balance, the Metabolic Response to Injury, Surgical Nutrition and Blood Transfusion 35.2 Basic Surgical Principles II: Shock and Surgical Critical Care, Hemorrhagic Shock and Massive Transfusion, ATLS Primary and Secondary Survey, Chest and Abdominal Trauma, Head and Spine Injury, Pelvic Fractures and Burns 35.3 Basic Surgical Principles III: Preoperative Assessment, Wound Healing, Surgical Infection and Asepsis, Postoperative Fever, Surgical Oncology, Immunology and Transplantation, Anesthesia and Patient Safety

36 Chapter 36: Surgery II: Abdomen, Breast & Hernia

36.1 Abdomen I: Esophagus (Hiatal Hernia, GERD, Achalasia, Caustic Injury, Barrett, Boerhaave, Mallory-Weiss, Cancer), Stomach and Duodenum (Peptic Ulcer Complications, Upper GI Bleeding, Gastric Cancer, GIST), Small Bowel (Obstruction, Ileus, Tumors, Typhoid and TB), Retroperitoneum and Abdominal Wall 36.2 Abdomen II: Gallstones, Cholecystitis, Choledocholithiasis and Cholangitis, Obstructive Jaundice, Liver (Cirrhosis, Portal Hypertension, Abscesses, Tumors and Hepatocellular Carcinoma), Pancreas (Acute and Chronic Pancreatitis, Pancreatic Cancer) and Spleen (Splenectomy, OPSI) 36.3 Abdomen III: Acute Appendicitis, Colonic Obstruction and Volvulus, Lower GI Bleeding, Diverticular Disease, Colorectal Polyps and Cancer, Hemorrhoids, Anal Fissure, Perianal Abscess and Fistula 36.4 Breast, Hernia and Skin and Soft Tissue: Benign Breast Masses, Breast Cancer Evaluation and Treatment, Groin and Abdominal Wall Hernias, Benign Skin and Soft-Tissue Tumors, Skin Cancers and Soft-Tissue Sarcoma

37 Chapter 37: Surgery III: Surgical Specialties

37.1 Head and Neck, Thyroid, Parathyroid, Endocrine and Bariatric Surgery and Otorhinolaryngology: Neck Masses and Head and Neck Cancer, Salivary Glands, Thyroid Nodules and Cancer, Goiter and Hyperthyroidism Surgery, Hyperparathyroidism, Adrenal Surgery, Bariatric Surgery, Nasal Polyps, Epistaxis, Vertigo, Hearing Loss and ENT Infections 37.2 Specialty I: Neurosurgery (Raised Intracranial Pressure and Herniation, Head Injury and Hematomas, Spontaneous Intracranial Hemorrhage, CNS and Peripheral Nerve Tumors, Spinal Cord Compression, Neurosurgical Infections) and Ophthalmology (Glaucoma, Cataract, Ophthalmic Emergencies) 37.3 Specialty II: Thoracic and Cardiovascular Surgery (Pleural Effusion and Empyema, Lung Cancer, Mediastinal Masses, Surgical Heart Disease, Aortic Aneurysm and Dissection, Peripheral Arterial and Venous Disease), Urology (Stones, Infections, Torsion, BPH, Urologic Tumors) and Gynecologic Surgery 37.4 Specialty III: Plastic and Reconstructive Surgery (Skin Grafts and Flaps, Cleft Lip and Palate, Facial Fractures, Hand Injuries), Orthopedics (Fractures, Dislocations, Bone and Joint Infections, Bone Tumors) and Pediatric Surgery (Hernias, CDH, Esophageal Atresia, Obstruction, Hirschsprung Disease, Neonatal Jaundice, Tumors)

38 Chapter 38: Medicine I: Cardiovascular, Digestive & Endocrine Medicine

38.1 Cardiovascular Medicine I: Hypertension and Secondary Causes, Dyslipidemia, Stable Angina and Acute Coronary Syndromes, Post-MI Complications, Heart Failure and Shock Syndromes 38.2 Cardiovascular Medicine II: Tachyarrhythmias and Bradyarrhythmias, Atrial Fibrillation, Sudden Cardiac Death and Brugada Syndrome, Cardiac Arrest, Valvular and Rheumatic Heart Disease, Infective Endocarditis, Myocarditis and Pericardial Disease 38.3 Gastroenterology and Hepatology: GERD and Peptic Ulcer Disease, Upper and Lower GI Bleeding, Diarrhea and GI Infections, Acute Pancreatitis and Biliary Disease, Viral Hepatitis, Cirrhosis and Portal Hypertension, Liver and GI Cancers 38.4 Endocrinology: Diabetes Mellitus Diagnosis, Treatment and Complications, DKA and HHS, Thyroid Disease, Pituitary Disorders, Adrenal Disorders (Cushing, Aldosteronism, Addison, Pheochromocytoma), Calcium and Parathyroid Disorders, Obesity and Metabolic Syndrome

39 Chapter 39: Medicine II: Hematology, Systemic Infections, Renal & Respiratory Medicine

39.1 Hematology, Immunology and Systemic Infections: Anemias (Iron Deficiency, Thalassemia, G6PD Deficiency, Megaloblastic, Hemolytic), Acute and Chronic Leukemias and Their Emergencies, Allergic Disorders, Dengue in Adults, COVID-19, Malaria and HIV/AIDS Opportunistic Infections 39.2 Nephrology: Acute Kidney Injury, Chronic Kidney Disease and Dialysis, Sodium and Potassium Disorders, Acid-Base Analysis, Urinary Tract Infections, Glomerular Diseases (Nephritic and Nephrotic), Kidney Stones, Renal Tumors and Sexually Transmitted Infections 39.3 Pulmonology and Critical Care: Acute Respiratory Failure and Oxygen Therapy, Bronchial Asthma, COPD, Community- and Hospital-Acquired Pneumonia, Pulmonary Tuberculosis and TB Infection, Pulmonary Embolism, Lung Cancer and ARDS

40 Chapter 40: Medicine III: Rheumatology, Dermatology, Neurology, Rehabilitation & Psychiatry

40.1 Rheumatology and Dermatology: Approach to Arthritis, Osteoarthritis, Rheumatoid Arthritis, Gout, Spondyloarthritis, SLE and Other Connective Tissue Diseases, Vasculitis and Myalgias, Bone Tumors, Common Skin Lesions, Skin Infections and Infestations, Eczema, Psoriasis, Severe Drug Eruptions and Skin Signs of Systemic Disease 40.2 Neurology and Rehabilitation Medicine: Stroke and TIA (Localization, Thrombolysis, Thrombectomy, Secondary Prevention), Intracranial Hemorrhage, Seizures and Status Epilepticus, Meningitis and Encephalitis, Tetanus and Rabies, Parkinsonism, Neuromuscular and Degenerative Diseases, Dementia, CNS Tumors, Post-Stroke Rehabilitation and Musculoskeletal Disorders 40.3 Psychiatry: Mental Status Examination, Depressive Disorders, Bipolar Disorder, Schizophrenia and Other Psychoses, Anxiety Disorders, OCD and Trauma-Related Disorders, Substance Use, and Acute Psychiatric Emergencies (Suicide Risk, Agitation, Withdrawal, Wernicke Encephalopathy)

13.6 Bioenergetics, the Citric Acid Cycle, Oxidative Phosphorylation, Muscle Energetics & Nucleotide Metabolism

Key Takeaways Explain This Topic AI

Each acetyl-CoA oxidized in the citric acid cycle yields 3 NADH, 1 FADH2 and 1 GTP (about 10 ATP); complete oxidation of glucose yields about 30 to 32 ATP.

Cyanide, carbon monoxide and azide block complex IV; rotenone blocks complex I; antimycin A blocks complex III; oligomycin blocks ATP synthase; uncouplers (2,4-dinitrophenol, high-dose aspirin, thermogenin) dissipate the proton gradient as heat.

Muscle draws first on ATP and creatine phosphate (seconds), then anaerobic glycolysis (up to about 1 to 2 minutes, lactate), then aerobic oxidation of glucose and fatty acids.

Gout follows uric acid overproduction or underexcretion; Lesch-Nyhan syndrome (HGPRT deficiency, X-linked) adds self-mutilation; allopurinol and febuxostat inhibit xanthine oxidase.

Adenosine deaminase deficiency causes SCID; orotic aciduria with megaloblastic anemia but normal ammonia indicates UMP synthase deficiency.

Last updated: October 2026

Why this area matters

The TOS area labeled "musculoskeletal system" lists:

"bioenergetics and thermodynamics, role of ATP, biologic oxidation, electron transport chain, oxidative phosphorylation";

"muscle energetics (glycolysis, Krebs cycle, creatine phosphate)";

"nucleic acid chemistry, diseases associated with purine and pyrimidine nucleotide metabolism".

These connect to cyanide and carbon monoxide poisoning, aspirin overdose, mitochondrial myopathy, rhabdomyolysis, gout and cancer chemotherapy.

Thermodynamic Principles and High-Energy Phosphate Energetics

Chemical reactions within biological systems obey the laws of thermodynamics. The standard free energy change ( Δ G ∘ ′ \Delta G^{\circ\prime} Δ G ∘ ′ ) denotes the net energy liberated or consumed under standard physiological conditions ( 25 ∘ C 25^\circ\text{C} 2 5 ∘ C , 1 atm 1\text{ atm} 1 atm , pH 7.0 \text{pH }7.0 pH 7.0 , and 1 M 1\text{ M} 1 M reactant concentrations):

Δ G = Δ G ∘ ′ + R T ln ⁡ ( [ Products ] [ Reactants ] ) \Delta G = \Delta G^{\circ\prime} + RT \ln \left( \frac{[\text{Products}]}{[\text{Reactants}]} \right) Δ G = Δ G ∘ ′ + RT ln ( [ Reactants ] [ Products ] ​ )

Exergonic Reactions ( Δ G < 0 \Delta G < 0 Δ G < 0 ): Proceed spontaneously with the net release of usable free energy.

Endergonic Reactions ( Δ G > 0 \Delta G > 0 Δ G > 0 ): Thermodynamically non-spontaneous and require energetic coupling to an exergonic driver.

Equilibrium ( Δ G = 0 \Delta G = 0 Δ G = 0 ): Forward and reverse reaction rates are equal, precluding net work.

Hydrolysis of the terminal phosphoanhydride bond of ATP to adenosine diphosphate (ADP) and inorganic phosphate ( P i P_i P i ​ ) yields a standard free energy change of approximately − 30.5 kJ/mol -30.5\text{ kJ/mol} − 30.5 kJ/mol ( − 7.3 kcal/mol -7.3\text{ kcal/mol} − 7.3 kcal/mol ):

ATP + H 2 O ⟶ ADP + P i ( Δ G ∘ ′ ≈ − 30.5 kJ/mol ) \text{ATP} + \text{H}_2\text{O} \longrightarrow \text{ADP} + P_i \quad (\Delta G^{\circ\prime} \approx -30.5\text{ kJ/mol}) ATP + H 2 ​ O ⟶ ADP + P i ​ ( Δ G ∘ ′ ≈ − 30.5 kJ/mol )

Certain intermediate metabolites carry even higher phosphate transfer potentials than ATP, permitting substrate-level phosphorylation. These include phosphoenolpyruvate (PEP, − 61.9 kJ/mol -61.9\text{ kJ/mol} − 61.9 kJ/mol ), 1,3-bisphosphoglycerate (1,3-BPG, − 49.4 kJ/mol -49.4\text{ kJ/mol} − 49.4 kJ/mol ), and creatine phosphate ( − 43.1 kJ/mol -43.1\text{ kJ/mol} − 43.1 kJ/mol ). Phosphorylation of ADP by PEP or 1,3-BPG directly yields ATP without requiring mitochondrial oxygen consumption.

The Citric Acid Cycle (Krebs Cycle): Stoichiometry and Regulatory Checkpoints

The Citric Acid Cycle occurs within the mitochondrial matrix, acting as the final common oxidative pathway for carbohydrates, lipids, and amino acids. Acetyl-CoA ( 2 C 2\text{C} 2 C ) condenses with oxaloacetate ( 4 C 4\text{C} 4 C ) to form citrate ( 6 C 6\text{C} 6 C ), catalyzed by citrate synthase.

High-Yield Krebs Cycle Reactions

Step Enzyme Substrates → \to → Products High-Energy Yield / Cofactors Regulation

1 Citrate Synthase Oxaloacetate + Acetyl-CoA → Citrate \text{Oxaloacetate} + \text{Acetyl-CoA} \to \text{Citrate} Oxaloacetate + Acetyl-CoA → Citrate Consumes H 2 O \text{H}_2\text{O} H 2 ​ O ; releases CoA-SH \text{CoA-SH} CoA-SH Inhibited by ATP, NADH, citrate, succinyl-CoA

2 Aconitase Citrate ↔ Isocitrate \text{Citrate} \leftrightarrow \text{Isocitrate} Citrate ↔ Isocitrate Iron-sulfur center ( [ 4 Fe − 4 S ] [4\text{Fe}-4\text{S}] [ 4 Fe − 4 S ] ) Inhibited competitively by fluorocitrate

3 Isocitrate Dehydrogenase Isocitrate → α -Ketoglutarate \text{Isocitrate} \to \alpha\text{-Ketoglutarate} Isocitrate → α -Ketoglutarate 1 NADH , releases CO 2 \text{CO}_2 CO 2 ​ Rate-limiting enzyme ; activated by ADP, inhibited by ATP and NADH

4 α \alpha α -Ketoglutarate Dehydrogenase α -Ketoglutarate → Succinyl-CoA \alpha\text{-Ketoglutarate} \to \text{Succinyl-CoA} α -Ketoglutarate → Succinyl-CoA 1 NADH , releases CO 2 \text{CO}_2 CO 2 ​ Same 5 coenzymes as PDH; inhibited by succinyl-CoA, NADH, arsenic

5 Succinyl-CoA Synthetase Succinyl-CoA → Succinate \text{Succinyl-CoA} \to \text{Succinate} Succinyl-CoA → Succinate 1 GTP (= 1 ATP 1\text{ ATP} 1 ATP via substrate-level phosphorylation) Reversible; generates free CoA

6 Succinate Dehydrogenase Succinate → Fumarate \text{Succinate} \to \text{Fumarate} Succinate → Fumarate 1 F A D H 2 FADH_2 F A D H 2 ​ Embedded in inner mitochondrial membrane as Complex II of the ETC

7 Fumarase Fumarate → L-Malate \text{Fumarate} \to \text{L-Malate} Fumarate → L-Malate Hydration reaction Stereospecific for L-malate

8 Malate Dehydrogenase L-Malate → Oxaloacetate \text{L-Malate} \to \text{Oxaloacetate} L-Malate → Oxaloacetate 1 NADH Driven forward by rapid oxaloacetate consumption

Stoichiometric Yield of the Citric Acid Cycle

Each turn of the Citric Acid Cycle per molecule of acetyl-CoA produces:

3 NADH 3\text{ NADH} 3 NADH ( 3 × 2.5 = 7.5 ATP 3 \times 2.5 = 7.5\text{ ATP} 3 × 2.5 = 7.5 ATP equivalents)

1 F A D H 2 1\text{ }FADH_2 1 F A D H 2 ​ ( 1 × 1.5 = 1.5 ATP 1 \times 1.5 = 1.5\text{ ATP} 1 × 1.5 = 1.5 ATP equivalents)

  • 1 GTP 1\text{ GTP} 1 GTP ( = 1.0 ATP = 1.0\text{ ATP} = 1.0 ATP equivalent)
  • 2 CO 2 2\text{ CO}_2 2 CO 2 ​

Total yield: 10 ATP 10\text{ ATP} 10 ATP equivalents per acetyl-CoA ( 20 ATP 20\text{ ATP} 20 ATP per original molecule of glucose).

Accounting for aerobic glycolysis ( 2 ATP + 2 NADH 2\text{ ATP} + 2\text{ NADH} 2 ATP + 2 NADH ) and the PDH reaction ( 2 NADH 2\text{ NADH} 2 NADH ), the complete oxidation of one glucose molecule yields 30 to 32 net ATP :

32 ATP 32\text{ ATP} 32 ATP via the malate-aspartate shuttle (predominant in liver, heart, and kidneys).

30 ATP 30\text{ ATP} 30 ATP via the glycerol-3-phosphate shuttle (predominant in skeletal muscle and brain, transferring electrons to F A D FAD F A D as F A D H 2 FADH_2 F A D H 2 ​ ).

The Electron Transport Chain and Oxidative Phosphorylation

Oxidative phosphorylation couples the transfer of electrons from NADH and F A D H 2 FADH_2 F A D H 2 ​ to molecular oxygen with the generation of ATP via a transmembrane proton gradient across the inner mitochondrial membrane (Peter Mitchell's chemiosmotic hypothesis).

Complex I (NADH-Ubiquinone Oxidoreductase): Translocates 4 H + 4\text{ H}^+ 4 H + per electron pair from matrix to intermembrane space.

Complex II (Succinate Dehydrogenase): Oxidizes F A D H 2 FADH_2 F A D H 2 ​ to transfer electrons to ubiquinone (Coenzyme Q). Translocates 0 H + 0\text{ H}^+ 0 H + .

Complex III (Ubiquinol-Cytochrome c Oxidoreductase / Cytochrome b c 1 bc_1 b c 1 ​ ): Q-cycle translocates 4 H + 4\text{ H}^+ 4 H + per pair.

Complex IV (Cytochrome c Oxidase): Contains heme a / a 3 a/a_3 a / a 3 ​ and copper centers ( C u A / C u B Cu_A/Cu_B C u A ​ / C u B ​ ). Reduces O 2 O_2 O 2 ​ to 2 H 2 O 2\text{ H}_2\text{O} 2 H 2 ​ O , translocating 2 H + 2\text{ H}^+ 2 H + .

Complex V ( F o F 1 F_oF_1 F o ​ F 1 ​ -ATP Synthase): Protons re-enter matrix through the F o F_o F o ​ stalk, rotating the γ \gamma γ -subunit and driving the condensation of ADP and P i P_i P i ​ into ATP in the F 1 F_1 F 1 ​ head.

Electron Transport Chain Inhibitors versus Uncouplers

Agent Target / Mechanism Effect on Respiration ( O 2 O_2 O 2 ​ Consumption) Effect on ATP Synthesis Effect on Proton Gradient

  • Rotenone, Amytal, MPTP Inhibits Complex I Decreased Decreased Decreased
  • Malonate Competitive inhibitor of Complex II Decreased Decreased Decreased
  • Antimycin A Inhibits Complex III Decreased Decreased Decreased

Cyanide ( C N − CN^- C N − ), Carbon Monoxide (CO), Azide, H 2 S H_2S H 2 ​ S Inhibits Complex IV (cytochrome a 3 a_3 a 3 ​ ) Decreased to zero Decreased to zero Decreased

Oligomycin Blocks F o F_o F o ​ proton channel of Complex V Decreased (coupled arrest) Arrested Increased (steep gradient prevents further pumping)

2,4-Dinitrophenol (DNP), Aspirin (overdose), Thermogenin (UCP-1) Uncouplers : Shuttles H + H^+ H + across inner membrane Greatly Increased Arrested Dissipated to zero ; energy released exclusively as heat (hyperthermia)

Mitochondrial Beta-Oxidation and the Carnitine Shuttle

During fasting and exercise, triacylglycerols stored in adipose tissue are hydrolyzed by adipose triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL) (activated by glucagon/epinephrine via PKA-mediated phosphorylation; inhibited by insulin). Free fatty acids circulate bound to albumin and enter peripheral tissues for β \beta β -oxidation within the mitochondrial matrix.

Activation and the Carnitine Shuttle

In the outer mitochondrial membrane, fatty acids are activated to fatty acyl-CoA by fatty acyl-CoA synthetase (thiokinase) , consuming two high-energy phosphate equivalents ( ATP → AMP + P P i \text{ATP} \to \text{AMP} + PP_i ATP → AMP + P P i ​ ). Fatty acyl-CoA cannot cross the inner mitochondrial membrane and relies on the Carnitine Shuttle ( Mnemonic: " CAR nitine = CAR nage of fatty acids in mitochondria"):

Carnitine Palmitoyltransferase-1 (CPT-1): Located on the outer mitochondrial membrane; transfers the acyl group from CoA to carnitine, forming acylcarnitine.

Crucial Allosteric Control: CPT-1 is potently inhibited by malonyl-CoA , preventing newly synthesized fatty acids from immediate futile oxidation.

Carnitine-Acylcarnitine Translocase: Shuttles acylcarnitine across the inner membrane while returning free carnitine to the intermembrane space.

Carnitine Palmitoyltransferase-2 (CPT-2): Located on the inner mitochondrial membrane; regenerates fatty acyl-CoA and free carnitine within the matrix.

The Four-Step β \beta β -Oxidation Spiral

Each turn of the mitochondrial β \beta β -oxidation spiral shortens the acyl chain by two carbons, releasing:

  • 1 FADH 2 1\text{ FADH}_2 1 FADH 2 ​ (via Acyl-CoA Dehydrogenase; feeds into Complex II / ubiquinone)
  • 1 NADH 1\text{ NADH} 1 NADH (via 3-Hydroxyacyl-CoA Dehydrogenase; feeds into Complex I)
  • 1 Acetyl-CoA 1\text{ Acetyl-CoA} 1 Acetyl-CoA (via β \beta β -Ketothiolase; feeds into the Krebs cycle)
  • A shortened fatty acyl-CoA ( n − 2 n-2 n − 2 carbons)
  • Medium-Chain Acyl-CoA Dehydrogenase (MCAD) Deficiency

MCAD deficiency is the most common inborn error of β \beta β -oxidation (autosomal recessive). Affected infants cannot oxidize medium-chain (C6–C10) fatty acids. During prolonged fasting or intercurrent viral infection, glucose stores are depleted, but hepatic β \beta β -oxidation fails to supply energy or acetyl-CoA for ketogenesis. Manifestations include:

Severe Hypoketotic Hypoglycemia: Profound hypoglycemia without detectable urinary or plasma ketone bodies.

Accumulation of C6–C10 acylcarnitines (octanoylcarnitine) in blood, with dicarboxylic aciduria (from compensatory ω \omega ω -oxidation in peroxisomes and ER).

Lethargy, seizures, hepatomegaly, hyperammonemia, and sudden death. Treatment involves avoidance of fasting and high-carbohydrate nutrition.

Muscle energetics

Energy system Time span Features

Stored ATP and creatine phosphate (phosphagen system) About 10 seconds of maximal effort Creatine kinase transfers phosphate from creatine phosphate to ADP; creatine is made from arginine, glycine and methionine; creatinine is its non-enzymatic breakdown product, excreted at a fairly constant rate in proportion to muscle mass

Anaerobic glycolysis Seconds to about 1 to 2 minutes Fast ATP from glycogen, with lactate accumulating. Type II (fast-twitch) fibers

Aerobic oxidation of glucose, fatty acids and ketones Minutes to hours Mitochondria-rich, myoglobin-rich type I (slow-twitch) fibers ; endurance training increases mitochondria

Myoglobin stores oxygen in muscle. It has a hyperbolic dissociation curve and higher affinity than hemoglobin.

Rhabdomyolysis (crush injury, extreme exertion, statins, heat stroke) releases myoglobin and CK, which can cause acute kidney injury and hyperkalemia.

Mitochondrial myopathies cause exercise intolerance and lactic acidosis. McArdle disease (no muscle glycogen phosphorylase) and CPT II deficiency cause exercise-induced myoglobinuria.

Muscle lacks glucose-6-phosphatase, so its glycogen fuels only the muscle itself.

Nucleic acid chemistry

Purines (two rings): adenine, guanine. Pyrimidines (one ring): cytosine, thymine (DNA), uracil (RNA).

A nucleoside is a base plus a sugar; a nucleotide is a nucleoside plus phosphate.

DNA is a double helix with A pairing with T (2 hydrogen bonds) and G pairing with C (3 hydrogen bonds). GC-rich DNA melts at a higher temperature.

RNA has ribose and uracil and is usually single-stranded. The 2'-OH makes RNA less stable than DNA.

Phosphodiester bonds link the 3'-OH of one sugar to the 5'-phosphate of the next, and strands run antiparallel.

Purine and pyrimidine metabolism

De novo purine synthesis:

The ring is built on PRPP , with atoms from glycine, aspartate, glutamine, CO2 and folate (N10-formyl-THF) .

The rate-limiting enzyme is glutamine-PRPP amidotransferase . The first purine made is IMP, which becomes AMP and GMP.

Salvage reuses bases through HGPRT (hypoxanthine and guanine) and APRT (adenine).

Pyrimidine synthesis:

The ring is made first: carbamoyl phosphate synthetase II in the cytosol, then aspartate, giving orotic acid .

It is then attached to PRPP, forming UMP through UMP synthase .

Thymidylate synthase (which needs N5,N10-methylene-THF ) converts dUMP to dTMP.

Ribonucleotide reductase forms deoxyribonucleotides.

Purine degradation runs from adenosine (by adenosine deaminase) to inosine, then hypoxanthine, then xanthine, and finally uric acid by xanthine oxidase .

Disorder Defect Features

Gout Overproduction (high cell turnover, PRPP synthetase overactivity, tumor lysis) or, more often, renal underexcretion (thiazides, low-dose aspirin, alcohol, kidney disease) Monosodium urate crystals ( needle-shaped, negatively birefringent ) cause acute arthritis (often the first MTP joint), tophi and urate stones

Lesch-Nyhan syndrome HGPRT deficiency (X-linked recessive) No purine salvage, so PRPP accumulates and de novo synthesis rises, with hyperuricemia , gout, intellectual disability, dystonia and self-mutilation (lip and finger biting)

Adenosine deaminase deficiency ADA (autosomal recessive) Toxic deoxyadenosine and dATP inhibit ribonucleotide reductase in lymphocytes, causing SCID ; first disease treated with gene therapy

Hereditary orotic aciduria UMP synthase Orotic acid in urine, megaloblastic anemia not corrected by B12 or folate , failure to thrive; normal ammonia (contrast with OTC deficiency, which has high ammonia); treated with uridine

Tumor lysis syndrome Rapid destruction of tumor cells Hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and acute kidney injury; prevented with hydration, allopurinol or rasburicase (rasburicase is contraindicated in G6PD deficiency)

Drugs acting on nucleotide metabolism:

Methotrexate inhibits dihydrofolate reductase.

5-fluorouracil inhibits thymidylate synthase.

Hydroxyurea inhibits ribonucleotide reductase.

6-mercaptopurine and azathioprine are purine analogs. Their toxicity rises with allopurinol, because xanthine oxidase helps degrade them.

Allopurinol and febuxostat inhibit xanthine oxidase.

Mycophenolate inhibits IMP dehydrogenase in lymphocytes.

Leflunomide inhibits dihydroorotate dehydrogenase.

Trimethoprim and pyrimethamine inhibit microbial dihydrofolate reductase.